Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients by Pierre Truntzer et al.
Truntzer et al. Radiation Oncology 2014, 9:259
http://www.ro-journal.com/content/9/1/259CASE REPORT Open AccessSuperior sulcus non small cell lung carcinoma:
retrospective analysis of 42 patients
Pierre Truntzer1, Delphine N Antoni1,2, Nicola Santelmo3, Catherine Schumacher1, Pierre-Emmanuel Falcoz3,
Elisabeth Quoix4, Jean-Pierre Steib5, Gilbert Massard3 and Georges Noël1,2*Abstract
Aims: Retrospective, monocentric analysis of localized superior sulcus non-small cell cancer (SS-NSCLC),
article management.
Materials and methods: Between 2000 and 2010, 42 patients have been treated for a SS-NSCLC. Median age was
54.7 years (34.5-86.8). Nineteen tumors (45.2%) were stage IIB, 18 were stage IIIA (42.9%) and 5 were stage IIIB (11.9%).
Twenty-two patients were treated by pre-operative radiotherapy or chemoradiotherapy, 20 received exclusive
radiotherapy or chemoradiotherapy. Preoperative and exclusive median radiotherapy doses were 46 Gy (40–47 Gy) and
51.8 Gy (40–70 Gy), respectively. All patients treated with chemotherapy received at least platinum. Mean follow up was
44.1 months (0–128 months).
Results: Local, loco-regional and metastatic relapses occurred in 11 (26.2%), 2 (4.8%) and 15 patients (35.7%),
respectively. Most common metastatic site was cerebral (7 patients, 46.7%). Median disease-free survival (DFS) was
9.7 months (8.9-10.4). One-, 2- and 5- years DFS rates were 44%, 33% and 26.5%, respectively. No prognostic factor was
identified.
Median overall survival (OS) was 22.6 months (10.4-34.8). One-, 2- and 5- years OS rates were 61.9%, 44.9% and 30.1%,
respectively. Univariate prognostic factors for OS were WHO (p = 0.027) and tumoral response (p = 0.05). In multivariate
analysis, independent favorable prognostic factors were WHO 0–1 (p = 0.017; OR = 0.316 [CI95% 0.123-0.81) and complete
response to treatment (p = 0.035; OR = 0.312 [IC95% 0.106-0.919]).
Conclusion: This study highlighted that a good performans status and complete response to treatment are independent
factors of OS, whatever the delivered treatment. Brain was the most common metastatic relapse site.
Keywords: Chemotherapy, Radiotherapy, Sulcus non-small cell cancer, Surgery, SurvivalIntroduction
Superior sulcus non-small cell lung cancers (SS-NSCLC)
represents less than 5% of the NSCLC [1]. In 1956,
Chardack and Mc Callum reported the case of one pa-
tient treated with surgery followed by adjuvant radiation
therapy delivering 65 Gy. This combined treatment allowed
a long term survival without relapse at 70 months [2]. In
1961, Shaw and al. reported a retrospective study of 18
patients treated with pre-operative radiotherapy [3].
This combined treatment improved overall survival (OS),* Correspondence: gnoel@strasbourg.unicancer.fr
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unless otherwise stated.with 9 patients surviving at one year and a maximal
disease-free survival (DFS) of 51 months. Thus, preopera-
tive radiotherapy followed by surgery became the reference
treatment for SS-NSCLC.
Pre-operative radiotherapy decreases the tumoral exten-
sion allowing a more complete resection, a lower local,
lymphatic and systemic tumoral spread, and thereafter an
improved local control. With a neoadjuvant radiotherapy,
DFS and OS were increased by 30% and 15%, respectively,
compared to surgery alone [4]. In order to improve these
results, neo-adjuvant chemoradiation has been used in a
phase II trial. In this trial, Fifty-seven patients among
76 (76%) underwent surgical resection, and pathologic
complete resection was achieved in 51 patients (68%).
There were 12 patients with pathologic complete responsel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by surgery became the cornerstone of treatment for
SS-NSCLC [6]. For non operable patients with localized
SS-NSCLC, a chemoradiation delivering at least 66 Gy in
2 Gy by fractions remains the standard of care [7].
In this retrospective institutional study, we report the
outcomes of patients treated with different schedules.
Material and methods
Between January 2000 and January 2010, 42 patients pre-
senting a SS-NSCLC whose disease (4,2 patients/year/
center) who met the study criteria were analyzed. Char-
acteristics of the patients are summarized in Table 1. There
were 11 women and 31 men (sex ratio 2,8). Mean age
at diagnosis was 54.7 years. WHO performans status
(WHO-PS) was 0–1 for 82.5% of the patients and 2 for
16.7% of the patients. Thirty-eight patients (90.5%) had
shoulder pain irradiating to the scapula, whereas C8-D1
neuralgia, rib lyses and Claude Bernard syndrome were
retrieved in 30 (71.4%), 20 (57.1%) and 4 patients, respect-
ively. Only 3 patients had a complete Pancoast Tobias
syndrome. These patients have been treated either by
neo-adjuvant or exclusive radiotherapy with or without
chemotherapy for IIB to IIIB SS-NSCLC SS-NSCLC.
Pre-therapeutic assessment
The pre-therapeutic assessment included past medical story,
clinical and biological exams and thoracic radiography.
Non-invasive exams consisted for overall patients in a
thoraco-abdominal and pelvic CT scan. Additional examsTable 1 Patient’s characteristics
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NS: non specified.included a cervical and thoracic MRI in 25 patients
(59.5%), a cerebral CT in 24 patients (57.1%), a PET CT in
24 patients (57.1%), a bone scintigraphy in 16 patients
(38.1%) and a cerebral MRI in 4 patients (9.5%). Invasive
exams consisted in a bronchoscopy for 38 patients
(90.5%), a CT guided pulmonary biopsy for 30 patients
(71.4%), a mediastinoscopy for 4 patients (10.8%). Staging
was re-assessed according to the 7th TNM classification.
Functional respiratory evaluation was realized for 40
patients (97.6%), a gazometry for 27 patients (64.3%),
a ventilation perfusion pulmonary scintigraphy for 15
patients (35.7%).
Therapeutic management
Patients received either a preoperative chemoradiotherapy
(RT-CT) or radiotherapy (RT) or an exclusive RT-CT
or RT (Table 2).
Chemotherapy
Thirty-six patients received chemotherapy. Median delay
between beginning of chemotherapy and radiotherapy was
5 weeks (0–18 weeks). Twenty-four patients received pre-
radiation chemotherapy. One, 2, 3 or 4 chemotherapy
cycles were delivered before start of radiotherapy in 12, 7,
3 and 2 patients, respectively. Seven patients received up-
front chemoradiotherapy. This combination was followed
by adjuvant chemotherapy for a total of 4 to 6 cycles. Two
patients were treated with a sequential chemotherapy and
radiation therapy. Two, 4, 10, 8 and 9 patients received
2, 3, 4, 5 and 6 cycles of chemotherapy, respectively.
Overall patients received platinum based doublets, eitherTable 2 treatment’s characteristic
Treatment # Patients % Patients
Chemotherapy 36 85.7
# Mean cycle (min-max) 4 (2–6)
Cisplatinum-vinorelbine 23 54.8
Carboplatin paclitaxel 10 23.8
Unknown 3 7.1%
Radiotherapy: total dose/dose per fraction
66 Gy/2 Gy 8 19
46 Gy/2 Gy 22 52.4
Miscellaneous 12 28.6
Surgery 22 50%
En bloc resection 2 9.5
En bloc resection + lymph node dissection 20 90.5
Treatment
Exclusive radiation treatment 3 7.1
Exclusive chemoradiotherapy 17 40.5
Radiation treatment + surgery 19 45.3
Chemoradiotherapy + surgery 3 7.1
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or association of carboplatin and paclitaxel (10 patients).
The details of chemotherapy were unknown for 3 patients.
Radiotherapy
Radiation treatment was delivered with 3D conformal
radiotherapy (3D-CRT) by linear accelerator (Linac) for
38 patients (90.5%) or by intensity modulated radiotherapy
(IMRT) with TomoTherapy HiArt® (Accuray Incorporated,
Sunnyvale CA) for 4 patients (9.5%). 3D-CRT was deliv-
ered by two to four photons beams of 6–25 MV. The
delineation of target volume and organs at risk was
performed on a dosimetric CT scan (General Electric
LightSpeed QX/i) with contrast injection and 3.75 mm
thin joint images. For 4 patients, triple acquisition with
blocked inspiration and expiration and free breathing
was realized in order to define tumoral movement dur-
ing the respiratory cycle [8]. For 8 patients a dosimetric
TEP CT has been fused with the dosimetric CT scan.
GTV T (gross tumor volume) was delineated on the
CT scan, CTV T (clinical target volume) was defined as
the GTV T with an automatic 3D margin of 8 mm for
adenocarcinomas, 6 mm for squamous cell carcinomas,
and 5 mm for other subtype [9]. PTV (planning target
volume) was CTV T with an automatic 3D 2 mm margin
when triple acquisition was done, whereas a margin of
10 mm head-feet and 5 mm in other directions was added
when no triple acquisition was performed. CTV N corre-
sponded to the node area with lymph nodes which
diameter reached 10 to 20 mm, presenting or not an
increased uptake of 18FDG on the TEP CT, or lymph
nodes smaller than 10 mm or greater than 20 mm but
presenting an increased uptake of 18FDG. PTV N was
defined adding a 5 mm margin around CTV N. Five
patients underwent mediastinal invaded lymph nodes
irradiation, 6 patients (treated before 2006) received
prophylactic lymph node irradiation and one patient
had both [10].
Surgery
Surgery was performed with a mean period of 9.5 weeks
(6.8-12.9) after radiation therapy completion. It consisted
in all cases in an en bloc resection lobectomy, with medi-
astinal lymph node dissection for 20 patients. When medi-
astinal lymph nodes dissection was performed, a mean of
15 lymph nodes (6–36) was removed.
Follow up
The response to the treatment was considered complete
(CR) if there was a radiological disappearance of the measur-
able disease or if ypT0N0 was obtained in the pathological
report. Partial response (PR) was a regression of more than
50% to the base line of the sum of the perpendicular diame-
ters of all the measurable disease, whereas progressivedisease was defined as an improvement of more than
25% of this sum. Stable disease (SD) corresponded in
the cases that did not meet these endpoints.
Post therapeutic follow-up consisted in a thoracic radi-
ography, cerebral and thoracoabdominal and pelvis CT
scan every 3 months the first year and more distanced the
years after.
Statistical analyses
Statistical test used were the chi2 or the Fischer exact test
for qualitative parameters and variance analyses or T test
for quantitative parameters. Overall survival (OS) and
disease-free survival (DFS) were analyzed with the Kaplan
Meyer method. OS was defined as the time between the
end of the first treatment and the patient’s death or last
news. DFS was the time between the end of the first treat-
ment and the first relapse (local, regional or metastatic).
Univariate analysis was realized to identify prognostic
factors. Parameters considered as significant were included
in a multifactorial analysis. Multifactorial analysis was per-
formed with a Cox regression. Overall analyzes were done
with IBM SPSS Statistics v20 software (IBM Inc., Armonk,
NY, USA).
Results
At time of diagnosis, 19 tumors were classified stage T3N0,
IIB (45.2%), 18 tumors, stage IIIA (42.9%, 1 T3N1, 3 T2N2,
14 T4N0) and 5 tumors, stage IIIB (11,9%, 2 T3N3, 2
T4N2, 1 T4N3).
Pathological diagnosis was obtained by bronchoscopy
in 19% and by CT guided biopsy in 71.4%. Pathology was
adenocarcinoma in 17 cases (40.5%), squamous cell car-
cinoma in 14 cases (33.3%), large cells carcinoma in 6
cases (14.3%) and miscellaneous in 5 cases (11.9%).
Treatment
Twenty-nine patients underwent neoadjuvant RT-CT (26
patients) or RT alone (3 patients) before surgery (Table 1).
Chemotherapy consisted in a cisplatine-vinorelbine com-
bination for 18 patients and carboplatine-paclitaxel in 6
cases, and was not mentioned for 2 patients. Median deliv-
ered irradiation dose was 46 Gy (40–47 Gy). Among these
29 patients, seven patients (24.1%) were not operated on,
because of progressive disease (3 patients), tumors invad-
ing Adamkiewitz or great vessel tumoral (3 patients) and
one patient had a large vertebral invasion. Only one
patient received complement radiotherapy to reach a
curative total dose of 66 Gy.
Thirteen patients received exclusive RT-CT (10 patients)
or RT alone (3 patients). Chemotherapy was cisplatine
vinorelbine for 5 patients, carboplatin paclitaxel for 4
patients, and was not mentioned for one patient. Median
delivered irradiation dose was 51.8 Gy (40–70 Gy).
Table 3 Overall treatment response
Treatment CR PR SD PD Unknown
Exclusive RT-CT 3/17 (18%) 5/17 (28%) 4/17 (24%) 3/17 (18%) 2/17 (12%)
Exclusive RT 0/3 0/3 2/3 1/3 0/3
RT-CT-surgery 7/19 (37%) 9/19 (47%) 2/19 (11%) 1/19 (5%) 0/3
RT-surgery 1/3 2/3 0/3 0/3 0/3
Total 11/42 (26%) 16/42 (38%) 8/42 (19%) 5/42 (12%) 2/42 (5%)
CR: complete response; PR: partial response; RT: radiation therapy; RT-CT: chemoradiotherapy concomitant SD: stable disease; PD: progressive disease.
Table 4 Pathological response for patients operated on
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Fifteen patients had chemotherapy related toxicities. Thir-
teen patients had hematoxicity (36.1%) complicated with
febrile neutropenia in 6 patients (16.7%). Seven patients
(19.4%) had grade 2 nausea and/or vomiting. One patient
developed, platinum-related, hearing loss. Four patients
died from infection during chemotherapy for relapse.
Nineteen patients (45.9%) developed radiation related
side effects. Complications were grade 1–2 for 17 patients
and grade 3 for 2 patients. Only for one patient the radi-
ation treatment was definitively stopped at 42 Gy on the
46 Gy scheduled.
Thirteen patients (59%) had post-surgery complications.
Complications were neuropathic pain (6 patients, 27.3%),
respiratory distress (3 patients, 13.6%), lung infection (3
patients, 13.6%), brachial plexite (2 patients) and haemoragia
in one patient. No patient died post operatively.
Tumoral response
Surgery was complete (R0) for 19 patients (86.4%) and
incomplete (R1) for 3 patients (13.6%) (Table 3). Surgical
section was invaded on the pleura for one patient, on
rib for another one and vertebral for the last one. Two
patients presented lymph nodes invasion. For 18 patients,
lymphadenectomy showed no invaded lymph node. For
two patients the data was missing.
Overall, complete, partial, stable, progressive or unknown
responses were retrieved in 11 patients (26%), 16 patients
(38%), 8 patients (19%), 5 patients (12%) and 2 patients
(5%), respectively (Table 4). One patient died during the
treatment from tumoral progression. Among operated
patients, complete pathological response (pT0N0) was
concluded in eight patients (36%) (Table 4).
Mean follow up was 44.1 months (1.3-128). Thirty pa-
tients (71%) were dead. Twenty died of tumoral evolution.
Overall survival (OS)
For all patients, median OS was 22.6 months (CI95%
10.4-34.8). One-, 2- and 5-years OS rates were 61.9%,
44.9% and 30.1%, respectively (Figure 1A). In univariate
analysis significant differences have been retrieved for tu-
moral response (p = 0.046) and WHO PS (p = 0.027). In
multivariate analysis, favorable OS prognostic factors were
complete response after treatment (p = 0.035; OR = 0.312[CI95% 0.106-0.919]) (Figure 2A) and WHO PS 0–1 (p =
0.071; OR = 0.316 [CI95% 0.123-0.817]) (Figure 2B).
Patients undergoing surgery had a median OS of
24 months (CI95% 0–48.7). One-, 2- and 5-years OS rates
were 63.6%, 54.2% and 37.5%, respectively. No significant
prognostic factor was identified in univariate or multivariate
analysis.
For patients who received exclusive RT-CT or RT,
median OS was 13.3 months (CI95% 4.1-22.5). One-, 2-
and 5-years OS rates were 60%, 35% and 25%, respectively.
No significant prognostic factor was found in univariate or
multivariate analysis. There was no significant difference in
terms of OS between surgery or not (p = 0.37) (Figure 3A).Disease free survival (DFS)
Local relapse was diagnosed in 11 patients (26.2%), loco-
regional in 2 patients (4.8%) and metastatic in 15 patients
(35.7%). Most common metastatic relapse was the brain (7
patients, 46.7%). Median DFS was 9.7 months (CI95 8.9-
10.4) (Figure 1B). One-, 2-, 3- years DFS rates were 44%,
33% and 26.5%, respectively. No significant prognostic
factor was found in univariate or multivariate analysis.
For patients undergoing surgery, local relapse was re-
trieved in 3 of them (14.3%) and metastatic in 10 patients
(45%). Most common metastatic relapse localization was
Figure 1 Overall survival (A), disease free survival (B).
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(CI95% 0–24.8). One-, 2-, 3- years DFS rates were 50%,
38.1% and 38.1%, respectively. No prognostic factor was
significant on univariate or multivariate analysis.
For patients undergoing exclusive RT/RTCT, local relapse
was diagnosed in 8 patients (40%), loco regional in 2 pa-
tients (10%) and metastatic in 5 patients (25%). Most com-
mon metastatic relapse localization was brain (3
patients, 60%). Median DFS was 9.2 months (CI95%
4.48-13.9). One-, 2-, 3- years DFS rates were 33.3%, 27.8%
and 13.9%, respectively. No prognostic factor was signifi-
cant on univariate or multivariate analysis. There was nosignificant difference in terms of DFS between surgery or
not (p = 0.4) (Figure 3B).
Discussion
The treatment of SS-NSCLC is an exemplary multidiscip-
linary management. Since the 50’s, the recommendations
have changed regularly. Since the incurability, with me-
dian OS between 3 and 14 months to an OS rates ranged
between 18 and 33 months with preoperative chemoradio-
therapy followed by en bloc resection for operable tumors.
The incidence of this type of tumor with this localization
is rare, the number of 4.2 patients/years in our study is
Figure 2 Overall survival according neoadjuvant treatment response (A), according performans status at diagnosis (B).
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this low incidence, analysis of a large number of pa-
tients is biased by the heterogeneity of treatments along
the large period needed to collect enough patients and
data [1,5,6,11-13].Two prospective studies have been published. The
SWOG-9416 phase II trial included 110 patients with
operable T3-T4 N0-1 SS-NSCLC and evaluated preopera-
tive chemoradiotherapy delivering 45 Gy in 25 fractions of
1.8 Gy associated with 2 cycles combined cisplatine and
Figure 3 Overall survival (A) and disease free survival (B) according to treatment with or without surgery.
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patients presenting NSCLC and analyzed preoperative
chemoradiotherapy delivering 45 Gy in split course
(27 Gy in 15 fractions of 1.8 Gy, one week rest and 18 Gyin 10 fractions) associated with 2 cycles of mitomycine,
vindesine and cisplatine [5].
The treatment completion rates were 76% in the both
SWOG-9416 [6,13] and, JCOG-9806 [5] trials. In our study,
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pleted treatment. This ratio is favorably comparable to the
prospective studies mentioned above.
In surgical cohorts, non-invaded surgical margins (R0)
are the determining outcome factor concerning OS and
DFS [1,12,14]. In the present study R0 margins rate was
86.3%, comparable to JCOG results (81.3%) [5], but lower
than those obtained in the SWOG trial (96%). Patients
deemed undergoing surgery have to be carefully selected
and spine MRI may be essential to improve this selection.
In order to get a higher rate of complete response to
neoadjuvant treatment, and to achieve more complete
resections, radiation dose escalation has been evaluated.
Kwong and al. reported retrospectively 36 patients, with
stage IIB to IV with one resectable metastasis [15].
Chemotherapy was associated with conformal 3D radi-
ation therapy at the dose of 45 Gy (25 fractions of 1.8 Gy)
delivered in the tumor and mediastinum, with a comple-
ment of 14.2 Gy to the tumoral site. Complete resection
was obtained in 100% of patients. In 2008, Kappers and al.
reported 17 patients treated before surgery with 66 Gy in
24 fractions of 2.75 Gy and weekly concomitant cisplatine.
R0 margins surgery was obtained for 12 patients [16].
Escalading the preoperative radiation dose, can improve
R0 surgical margins rate and complete response to neoad-
juvant treatment. However, this increasing of dose can
lead in some complications. In our series, with classical
doses, relapse rates after surgery remain low (14.3%) and
are comparable with the rates obtained in the SWOG and
JCOG cohorts: 23% and 13%, respectively [1,5,13].
Histological complete response could be a surrogate of
overall survival. In the SWOG and JCOG trials, the rates
were 33.7% and 16%, respectively [1,5,13]. In our study,
8 patients on 22 undergoing surgery (36%) had histo-
logical complete response. It seems that, the rate can be
improved up to 40-47% by the increasing of the dose
[15,16]. However, the benefit of dose escalation remains
to be proved.
Median OS and Two- 3- and 5-years OS rates of our
study were favorably comparable with those obtained in
the SWOG and JCOG trials [5,6,13].
For patients with localized, but non-operable tumors
(Stage IIIA with N2 or IIIB), the reference treatment
remains chemoradiotherapy. Actually, the recommended
dose is 66 Gy in 33 fractions of 2Gy. De Bari and al. evalu-
ated, prospectively, 14 patients treated with chemoradio-
therapy with a median radiation dose of 72 Gy (64–74) in
2 Gy fractions [17]. Median OS was 20 months. Two pa-
tients initially considered as non-operable, presented a
partial response and have been operated on. Pathology did
not find any tumor. No complication has been reported.
The increase of dose for all the non-operable or limit of
operability patients becomes allowed by the use of in-
tensity modulated radiotherapy (IMRT) or proton therapy[18]. Limiting irradiated volumes, surgery could be feasible
without increase of complication even if radiation dose
has been increased. This schedule avoids split course
schedule less efficient than continuous irradiation. This
proposal still remains to be proved.
Some patients can be at the limit of the resection pos-
sibility at presentation. Neoadjuvant treatment could allow
surgery. In absence of response, total radiation has to be
increased to reach curative dose, and this with a short gap
between the both irradiation periods. The evaluation of
the response remains difficult. In SWOG study, 72%
patient considered as PR at the radiological evaluation
were indeed pathologically CR, and 65% considered as
SD were CR or with few residual tumoral foci. The TEP
CT could be helping but an improvement of this tech-
nic is needed to use it as an efficient exam in this indi-
cation [19].
Because of the risk of brain metastasis as first relapse
pattern, a prophylactic brain irradiation can be discussed.
However, RTOG trial concluded to a decrease of brain
metastasis relapse with irradiation but did not show any
overall survival advantage of this irradiation in advanced
NSCLC and an increase of memory decline risk [20,21].
Conclusion
Although our series is retrospective, number of patients
and delivered treatments are comparable with previously
published retrospective studies. Our results are highly com-
parable with those of prospective controlled studies.
In addition, we have showed, that following closely the
treatment guidelines, complete resection can be achieved
and that complete pathology response is obtained in more
than one quarter of the treated cases. We also reported a
high risk of brain metastasis evolution in the patients with
controlled disease. This observation highly questions about
the prophylactic brain irradiation.
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